US2021308129A1PendingUtilityA1

Treating sexual desire disorders with flibanserin

Assignee: SPROUT PHARMACEUTICALS INCPriority: Oct 20, 2001Filed: Jun 18, 2021Published: Oct 7, 2021
Est. expiryOct 20, 2021(expired)· nominal 20-yr term from priority
A61K 31/496
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Claims

exact text as granted — not AI-modified
1 . A method of treating decreased sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 
     
     
         2 . The method according to  claim 1 , wherein the patient is female. 
     
     
         3 . The method according to  claim 1 , wherein the patient is male. 
     
     
         4 . The method according to  claim 1 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         5 . The method according to  claim 1 , wherein the amount administered is between about 1 mg and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         6 . The method according to  claim 1 , wherein the amount administered is in a dosage unit containing between about 0.01 ma and 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         7 . The method according to  claim 1 , wherein the amount administered is in a dosage unit containing between about 0.1 mg and 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         8 . A method of treating absent sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 
     
     
         9 . The method according to  claim 8 , wherein the patient is female. 
     
     
         10 . The method according to  claim 8 , wherein the patient is male. 
     
     
         11 . The method according to  claim 8 , wherein the amount administered is between about 2 mg and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         12 . The method according to  claim 8 , wherein the amount administered is between about 0.1 mg and 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         13 . The method according to  claim 8 , wherein the amount administered is in a dosage unit containing about 150 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         14 . A method of treating inhibited sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 
     
     
         15 . The method according to  claim 14 , wherein the patient is female. 
     
     
         16 . The method according to  claim 14 , wherein the patient is male. 
     
     
         17 . The method according to  claim 14 , wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         18 . The method according to  claim 14 , wherein the amount administered is in a dosage unit containing about 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         19 . The method according to  claim 14 , wherein the amount administered is in a dosage unit containing about 80 mg, of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 
     
     
         20 . The method according, to  claim 14 , wherein the amount administered is in a dosage unit containing about 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

Join the waitlist — get patent alerts

Track US2021308129A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.